Physician profile
John W Willis
NPI 1467550095
$2,097.93
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $448 · 2021: $39.55 · 2022: $59.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.72 | 2019-2022 | |
| Amarin Pharma, INC. | $229.08 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $207.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $186.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $160.95 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $111.89 | 2020 | |
| Lilly USA, LLC | $110.96 | 2019-2020 | |
| Amgen INC. | $92.44 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $83.75 | 2019 | |
| Pfizer INC. | $78.43 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $77.51 | 2019-2020 | |
| Astellas Pharma US INC | $72.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $61.10 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.74 | 2019 | |
| Genentech USA, INC. | $26.51 | 2019-2020 | |
| Metuchen Pharmaceuticals | $15.08 | 2019 | |
| Medtronic Minimed, INC. | $12.64 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.